Identifying Novel Therapeutic Combinations with 131I-MIBG to Treat Relapsed and Refractory Neuroblastoma |
The Regents of the University of California San Francisco / William Clay Gustafson, M.D., Ph.D. |
Reach Grants |
2014 |
California |
LSD1 Inhibition to Treat T-cell Acute Lymphoblastic Leukemia/Lymphoma |
University of Virginia, School of Medicine / Michael Engel, MD/PhD |
Reach Grants |
2016 |
Virginia |
Immunoglobulin High-Throughput Sequencing for Refining Risk Stratification in Infant B-ALL |
University of Rochester / Carol Fries Simpson, MD |
Reach Grants |
2023 |
New York |
Identification of Aberrantly Methylated Differentially Expressed Genes to Distinguish High- vs. Low-Risk Retinoblastoma |
Children’s Hospital Los Angeles / Jesse Berry, MD |
Reach Grants |
2023 |
California |
Preclinical Development of a First-in-Class PCNA Inhibitor for Treating Neuroblastoma |
City of Hope National Medical Center / Linda Malkas, PhD |
Reach Grants |
2019 |
California |
Optimization of Drug Efflux and Brain Clearance to Improve CED of Targeted Therapy to H3K27M DMG |
Mayo Clinic / David Daniels, MD/PhD |
Reach Grants |
2021 |
Minnesota |
Generation of CMV-specific CD19 CAR T cells Using Cytokine Capture Followed by Lentiviral Transduction and Expansion |
Research Institute at Nationwide Children's Hospital / Margaret Lamb, MD |
Reach Grants |
2019 |
Ohio |
Novel Genomic Diagnostics for Intracranial Germ Cell Tumors |
Connecticut Children’s Medical Center Foundation, Inc. / Ching Lau, MD/PhD |
Reach Grants |
2021 |
Connecticut |
Targeting Novel Pediatric-Specific FLT3 Mutations |
Fred Hutchinson Cancer Research Center / Soheil Meshinchi, MD,PhD |
Reach Grants |
2015 |
Washington |
Therapeutic Targeting of PGBD5-induced DNA Repair Dependency in Pediatric Solid Tumors |
Memorial Sloan-Kettering Cancer Center / Alex Kentsis, MD/PhD |
Reach Grants |
2017 |
New York |